January 17, 2015
On Jan. 9, the U.S. Food and Drug Administration (FDA) approved a three-in-one test that detects HIV, hepatitis C and hepatitis B.
The test, manufactured by Roche, is the second version of the "cobas TaqScreen MPX Test." This updated version provides increased sensitivity and is the only test approved by the FDA to detect the three aforementioned viruses together.
The real-time, multi-dye PCR assay will be used to test "donations of human whole blood and blood components including source plasma," according to Roche's press release.
"The combination of viral target detection and identification steps on a fully automated system offers workflow advantages to blood and plasma testing centers by eliminating the need for consecutive rounds of testing, and facilitating earlier donor counseling in the event of a positive result," the manufacturer stated.
Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Sex and the HIV Reservoir: New Research Points to the Powerful Effect of Estrogen|
|First U.S. Failure of Truvada as PrEP Is Reported at IDWeek|
|Post-AIDS 2018 Updates on HIV Cure Research|
|On-Demand PrEP Is Great. Now, What About Women?|
|High Rates of Anal HPV Infection in Gay Men Using PrEP in IPERGAY: The Role of Vaccination|